This site is intended for healthcare professionals

Data Monitoring Committee recommends phase III clinical trial of omecamtiv mecarbil in patients with Heart failure continue without changes.-Amgen + Cytokinetic s+ Servier.

Read time: 1 mins
Published:27th Feb 2020
Condition: Heart Failure
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest